Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SQZ-AAC-HPV in HPV16+ solid tumors
NCT04892043Phase 1Terminated
- Sponsor
- SQZ Biotechnologies
- Start
- Aug 2021
- Primary completion
- Nov 2023
- Modality
- Tissue Cells, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of SQZ-AAC-HPV in solid tumor (2 arms), sponsored by SQZ Biotechnologies. Primary endpoints: Treatment-Emergent Adverse Events at 1 year and Dose-Limiting Toxicity at 28 days. Started Aug 2021; status: terminated.
02
Drugs
SQZ-AAC-HPV
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04892043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04892043.